BR-750;Wy8678 acetate

Base Information

• Chemical Name: BR-750;Wy8678 acetate
• CAS No.: 23256-50-0
• Molecular Formula: C8H8Cl2N4•C2H4O2
• Molecular Weight: 291.137
• Hs Code.: 2928002500
• European Community (EC) Number: 245-534-7
• DSSTox Substance ID: DTXSID101017207
• Mol file: 23256-50-0.mol

Synonyms:23256-50-0;BR-750;Wy8678 acetate;acetic acid;2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine;SCHEMBL9580574;DTXSID101017207;HMS2232H14;HMS3266N20;HMS3369P04;HMS3652O06;AKOS016339641;AKOS030228360;KS-1362;FT-0630497;G0456;2-(2,6-Dichlorobenzylidene)hydrazinecarboximidamide acetate (1:1)

Chemical Property of BR-750;Wy8678 acetate

Chemical Property:

• Appearance/Colour: white solid
• Vapor Pressure: 8.63E-07mmHg at 25°C
• Melting Point: 227-229℃ (decomposition)
• Boiling Point: 405.7 °C at 760 mmHg
• Flash Point: 199.1 °C
• PSA: 111.56000
• Density: g/cm³
• LogP: 3.09220
• Storage Temp.: Store at RT
• Solubility.: H2O: 11 mg/mL
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 4
• Rotatable Bond Count: 2
• Exact Mass: 290.0337310
• Heavy Atom Count: 18
• Complexity: 259

Purity/Quality:

98%,99%, ^*data from raw suppliers

Guanabenz Acetate ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xn
• Hazard Codes: Xn
• Statements: 22
• Safety Statements: 22-36/37/39-45

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: CC(=O)O.C1=CC(=C(C(=C1)Cl)C=NN=C(N)N)Cl
• Recent EU Clinical Trials: PROTEIN MISFOLDING, AMYOTROPHIC LATERAL SCLEROSIS AND GUANABENZ: A PHASE II RCT WITH FUTILITY DESIGN
• Uses: antihypertensive α2-adrenergic agonist and IGRS selective ligand
• Clinical Use: Overall, the therapeutic applications for guanabenz are similar to those of clonidine and other α2-adrenergic agonists. One advantage for guanabenz is its once-a-day dosing schedule. Guanabenz has been used in diabetic patients with hypertension without adverse effect on the control of or therapy for diabetes, and it has been effective in hypertensive patients with chronic obstructive pulmonary disease, including asthma, chronic bronchitis, or emphysema. Guanabenz has been used alone or in combination with naltrexone in the management of opiate withdrawal in patients physically dependent on opiates and undergoing detoxification. Guanabenz also has been used as an analgesic in a limited number of patients with chronic pain